Taysha Gene Therapies, Inc. (TSHA) shareholders
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (9.90%), Rajeev Shah (9.90%) and 1 more | 32,886,242 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 27,662,481 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Paul B Manning Joint filing with The Paul B. Manning Revocable Trust dated May 10, 2000 (5.60%) | 25,601,111 | 9.80% | 13D (active) amendment | May 30, 2025 |
| RA Capital Healthcare Fund, L.P. Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 25,345,988 | 9.90% | 13G (passive) amendment | Jun 30, 2025 |
| Avoro Capital Advisors LLC Joint filing with Behzad Aghazadeh (9.99%) | 23,094,444 | 9.99% | 13G (passive) | Sep 30, 2024 |
| Roderick Wong Joint filing with RTW Investments, LP (7.00%) | 20,689,084 | 7.00% | 13G (passive) amendment | Mar 31, 2026 |
| RTW Investments, LP Joint filing with Roderick Wong, M.D. (9.99%) | 20,673,307 | 9.99% | 13G (passive) amendment | Mar 31, 2025 |
| Ryan Wilder Joint filing with Vestal Point Capital, LP (6.30%) | 18,000,000 | 6.30% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 17,852,291 | 6.50% | 13G (passive) amendment | Dec 31, 2025 |
| Morgan Stanley Joint filing with Morgan Stanley Capital Services LLC (5.00%) | 16,244,339 | 5.10% | 13G (passive) amendment | Jun 30, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (6.20%) | 15,627,822 | 6.20% | 13G (passive) amendment | Jun 30, 2025 |
| Vestal Point Capital, LP Joint filing with Ryan Wilder (5.00%) | 13,750,000 | 5.00% | 13G (passive) | Dec 31, 2025 |
| Goldman Sachs & Co. LLC Joint filing with The Goldman Sachs Group, Inc. (5.10%) | 12,748,968 | 5.10% | 13G (passive) | Jun 26, 2025 |
| Roderick Wong, M.D. Joint filing with RTW Investments, LP (5.90%) | 12,368,334 | 5.90% | 13G (passive) amendment | Dec 31, 2024 |
| Octagon Capital Advisors LP Joint filing with Octagon Investments Master Fund (5.10%), Ting Jia (5.10%) | 10,450,000 | 5.10% | 13G (passive) | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TSHA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 23,888,888 | 7.33% | $162.68M | +2,188,888 | 1.46% |
| Ra Capital Management, L.P. | 23,555,648 | 7.23% | $160.41M | – | 1.39% |
| Goldman Sachs Group Inc | 22,713,118 | 6.97% | $154.68M | +343,473 | 0.01% |
| BlackRock, Inc. | 20,691,927 | 6.35% | $140.91M | +2,326,319 | 0.00% |
| Vestal Point Capital, LP | 19,415,000 | 5.96% | $132.22M | +1,415,000 | 3.09% |
| Morgan Stanley | 16,487,479 | 5.06% | $112.28M | −1,477,892 | 0.01% |
| Rtw Investments, LP | 13,560,258 | 4.16% | $92.35M | −119,990 | 0.79% |
| FMR LLC | 13,336,413 | 4.09% | $90.82M | −984,842 | 0.00% |
| Vanguard Capital Management LLC | 12,478,595 | 3.83% | $84.98M | +2,247,093 | 0.00% |
| State Street Corp | 11,421,920 | 3.51% | $77.78M | +212,842 | 0.00% |
| Siren, L.L.C. | 9,846,579 | 3.02% | $67.06M | +1,016,666 | 1.36% |
| Octagon Capital Advisors LP | 9,693,244 | 2.97% | $66.01M | +833,333 | 5.93% |
| Geode Capital Management, LLC | 6,560,394 | 2.01% | $44.69M | +1,028,439 | 0.00% |
| Polar Capital Holdings Plc | 5,117,133 | 1.57% | $34.85M | −537,207 | 0.08% |
| Mpm Bioimpact LLC | 4,500,000 | 1.38% | $30.65M | New | 1.87% |
| D. E. Shaw & Co., Inc. | 4,398,652 | 1.35% | $29.95M | −28,649 | 0.01% |
| Baker Bros. Advisors LP | 4,004,756 | 1.23% | $27.27M | – | 0.14% |
| Wellington Management Group Llp | 3,975,605 | 1.22% | $27.07M | +3,349,244 | 0.00% |
| Healthcare Of Ontario Pension Plan Trust Fund | 3,885,501 | 1.19% | $26.46M | +1,002,200 | 0.04% |
| Casdin Capital, LLC | 3,250,000 | 1.00% | $22.13M | – | 1.11% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 209 | 300M | 91.9% | 42 / 99 | 41 / 22 | 48M | 14M |
| Q1 2026 | 191 | 266M | 81.6% | 35 / 69 | 49 / 35 | 39M | 28M |
| Q4 2025 | 195 | 269M | 82.6% | 64 / 62 | 46 / 22 | 42M | 35M |
| Q3 2025 | 155 | 265M | 81.3% | 28 / 61 | 35 / 20 | 35M | 28M |
| Q2 2025 | 150 | 258M | 79.3% | 44 / 48 | 34 / 20 | 96M | 5M |
| Q1 2025 | 127 | 167M | 51.2% | 22 / 39 | 31 / 25 | 22M | 22M |
| Q4 2024 | 131 | 167M | 51.4% | 28 / 45 | 28 / 16 | 36M | 26M |
| Q3 2024 | 120 | 160M | 49.1% | 32 / 45 | 16 / 18 | 28M | 17M |
| Q2 2024 | 107 | 161M | 49.4% | 36 / 28 | 22 / 38 | 35M | 24M |
| Q1 2024 | 109 | 151M | 46.2% | 36 / 29 | 27 / 14 | 46M | 26M |
| Q4 2023 | 87 | 130M | 40.0% | 32 / 30 | 11 / 8 | 24M | 24M |
| Q3 2023 | 63 | 130M | 39.9% | 35 / 14 | 6 / 11 | 120M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
163 funds held TSHA in Q2 2026, 65% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TSHA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 9,138,043 | 2.80% | $62.23M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 6,245,134 | 1.92% | $42.53M | 0.05% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 5,565,638 | 1.71% | $37.90M | 0.35% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 4,176,103 | 1.28% | $24.51M | 0.02% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 3,044,554 | 0.93% | $20.73M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 2,622,724 | 0.80% | $15.37M | 0.05% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 2,213,229 | 0.68% | $15.07M | 0.10% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,687,467 | 0.52% | $11.49M | 0.13% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,147,608 | 0.35% | $6.74M | 0.02% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 1,134,540 | 0.35% | $6.66M | 0.04% | May 31, 2026 |
| Fidelity Growth Company K6 Fund | 1,098,103 | 0.34% | $6.45M | 0.02% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 1,069,955 | 0.33% | $6.28M | 0.03% | May 31, 2026 |
| Select Biotechnology Portfolio | 940,476 | 0.29% | $5.52M | 0.10% | May 31, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 810,815 | 0.25% | $5.52M | 0.10% | Jun 30, 2026 |
| Fidelity Series Growth Company Fund | 759,920 | 0.23% | $4.46M | 0.02% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sukumar Nagendran | President and Head of R&D, Director | 936,410 | 0.29% | Jul 10, 2026 |
| Sean P. Nolan | Chief Executive Officer, Director | 4,443,802 | 1.36% | Jan 27, 2026 |
| Kamran Alam | CHIEF FINANCIAL OFFICER | 1,442,131 | 0.44% | Feb 6, 2026 |
| Laura Sepp-Lorenzino | Director | 127,178 | 0.04% | Jun 2, 2026 |
| Alison S. Long | Director | 127,178 | 0.04% | Jun 2, 2026 |
| Phillip B. Donenberg | Director | 241,289 | 0.07% | Jun 2, 2026 |
| John A. Stalfort III | Director | 2,060,849 | 0.63% | Jun 2, 2026 |
| Paul B. Manning | 10% owner | 4,175,037 | 1.28% | Jun 3, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Sukumar Nagendran President and Head of R&D, Director | Jul 10, 2026 | Sale(10b5-1 plan) | −200,000 | $6.24 | $1.25M | 936,410 |
| Phillip B. Donenberg Director | Jun 1, 2026 | Award | +21,335 | – | – | 241,289 |
| John A. Stalfort III Director | Jun 1, 2026 | Award | +21,335 | – | – | 1,176,559 |
| Laura Sepp-Lorenzino Director | Jun 1, 2026 | Award | +21,335 | – | – | 127,178 |
| Alison S. Long Director | Jun 1, 2026 | Award | +21,335 | – | – | 127,178 |
| Sukumar Nagendran President and Head of R&D, Director | Apr 10, 2026 | Option exercise | +19,021 | $1.71 | $32.53K | 1,336,410 |
| Sukumar Nagendran President and Head of R&D, Director | Apr 10, 2026 | Sale(10b5-1 plan) | −200,000 | $4.46 | $892.00K | 1,136,410 |
| Kamran Alam CHIEF FINANCIAL OFFICER | Feb 4, 2026 | Sale | −1,655 | $4.52 | $7.48K | 1,442,131 |
| Kamran Alam CHIEF FINANCIAL OFFICER | Jan 26, 2026 | Sale | −23,849 | $4.61 | $109.94K | 1,443,786 |
| Sean P. Nolan Chief Executive Officer, Director | Jan 26, 2026 | Sale | −41,312 | $4.61 | $190.45K | 2,908,257 |
| Sukumar Nagendran President and Head of R&D, Director | Jan 26, 2026 | Sale | −26,918 | $4.61 | $124.09K | 1,317,389 |
| Kamran Alam CHIEF FINANCIAL OFFICER | Jan 23, 2026 | Sale | −78,968 | $4.75 | $375.10K | 1,467,635 |
| Sean P. Nolan Chief Executive Officer, Director | Jan 23, 2026 | Sale | −136,789 | $4.75 | $649.75K | 2,949,569 |
| Sukumar Nagendran President and Head of R&D, Director | Jan 23, 2026 | Sale | −89,132 | $4.75 | $423.38K | 1,344,307 |
| Sean P. Nolan Chief Executive Officer, Director | Jan 12, 2026 | Award | +1,008,000 | – | – | 3,086,358 |
| Sukumar Nagendran President and Head of R&D, Director | Jan 12, 2026 | Award | +427,000 | – | – | 1,433,439 |
| Sukumar Nagendran President and Head of R&D, Director | Jan 12, 2026 | Sale(10b5-1 plan) | −200,000 | $4.71 | $942.00K | 1,006,439 |
| Sukumar Nagendran President and Head of R&D, Director | Jan 12, 2026 | Option exercise | +111,324 | $0.70 | $77.93K | 1,117,763 |
| Sukumar Nagendran President and Head of R&D, Director | Jan 12, 2026 | Option exercise | +88,676 | $1.71 | $151.64K | 1,206,439 |
| Kamran Alam CHIEF FINANCIAL OFFICER | Jan 12, 2026 | Award | +359,000 | – | – | 1,546,603 |
| Sukumar Nagendran President and Head of R&D, Director | Dec 1, 2025 | Option exercise | +260,047 | $1.71 | $444.68K | 1,266,486 |
| Sukumar Nagendran President and Head of R&D, Director | Dec 1, 2025 | Sale | −260,047 | $4.51 | $1.17M | 1,006,439 |
| Sukumar Nagendran President and Head of R&D, Director | Nov 28, 2025 | Option exercise | +70,172 | $0.70 | $49.12K | 1,076,611 |
| Sukumar Nagendran President and Head of R&D, Director | Nov 28, 2025 | Option exercise | +39,953 | $1.71 | $68.32K | 1,116,564 |
| Sukumar Nagendran President and Head of R&D, Director | Nov 28, 2025 | Sale | −110,125 | $4.75 | $523.09K | 1,006,439 |
| Sukumar Nagendran President and Head of R&D, Director | Sep 10, 2025 | Sale(10b5-1 plan) | −200,000 | $3.23 | $646.00K | 1,006,439 |
| Sukumar Nagendran President and Head of R&D, Director | Sep 10, 2025 | Option exercise | +41,150 | $0.70 | $28.80K | 1,206,439 |
| Kamran Alam CHIEF FINANCIAL OFFICER | Aug 21, 2025 | Sale | −54,491 | $2.85 | $155.30K | 1,187,603 |
| Sukumar Nagendran President and Head of R&D, Director | Aug 21, 2025 | Sale | −57,054 | $2.85 | $162.60K | 1,165,289 |
| Laura Sepp-Lorenzino Director | Jun 2, 2025 | Award | +56,623 | – | – | 105,843 |
| Alison S. Long Director | Jun 2, 2025 | Award | +56,623 | – | – | 105,843 |
| Phillip B. Donenberg Director | Jun 2, 2025 | Award | +56,623 | – | – | 219,954 |
| John A. Stalfort III Director | Jun 2, 2025 | Award | +56,623 | – | – | 1,155,224 |
| Paul B. Manning 10% owner | May 30, 2025 | Buy | +750,000 | $2.75 | $2.06M | 2,841,704 |
| Kamran Alam CHIEF FINANCIAL OFFICER | Mar 11, 2025 | Tax withholding | −29,843 | $1.69 | $50.43K | 1,242,094 |
| Sukumar Nagendran President and Head of R&D, Director | Jan 2, 2025 | Award | +324,500 | – | – | 1,222,343 |
| Kamran Alam CHIEF FINANCIAL OFFICER | Jan 2, 2025 | Award | +431,000 | – | – | 1,271,937 |
| Sean P. Nolan Chief Executive Officer, Director | Jan 2, 2025 | Award | +892,500 | – | – | 2,078,358 |
| Paul B. Manning 10% owner | Jun 27, 2024 | Buy | +1,333,333 | $2.25 | $3.00M | 1,333,333 |
| Alison S. Long Director | May 29, 2024 | Award | +49,220 | – | – | 49,220 |
| Phillip B. Donenberg Director | May 29, 2024 | Award | +49,220 | – | – | 163,331 |
| Laura Sepp-Lorenzino Director | May 29, 2024 | Award | +49,220 | – | – | 49,220 |
| John A. Stalfort III Director | May 29, 2024 | Award | +49,220 | – | – | 1,098,601 |
| Kamran Alam CHIEF FINANCIAL OFFICER | Feb 2, 2024 | Tax withholding | −1,288 | $1.51 | $1.94K | 840,937 |
| Sukumar Nagendran President and Head of R&D, Director | Jan 2, 2024 | Award | +863,617 | – | – | 897,843 |
| Sean P. Nolan Chief Executive Officer, Director | Jan 2, 2024 | Award | +1,184,688 | – | – | 1,185,858 |
| Kamran Alam Chief Financial Officer | Jan 2, 2024 | Award | +590,413 | – | – | 842,225 |
| Paul B. Manning 10% owner | Nov 17, 2023 | Buy | +100,000 | $1.63 | $163.00K | 16,566,667 |
| Kamran Alam Chief Financial Officer | Aug 24, 2023 | Sale(10b5-1 plan) | −33,000 | $2.33 | $76.89K | 258,042 |
| Sean P. Nolan Chief Executive Officer, Director | Aug 16, 2023 | Buy | +444,444 | $0.90 | $400.00K | 1,535,545 |
| Paul B. Manning 10% owner | Aug 16, 2023 | Buy | +16,466,667 | $0.90 | $14.82M | 16,466,667 |
| John A. Stalfort III Director | Aug 16, 2023 | Gift | +50,000 | – | – | 1,049,381 |
| John A. Stalfort III Director | Aug 16, 2023 | Buy | +388,889 | $0.90 | $350.00K | 999,381 |
| John A. Stalfort III Director | Aug 16, 2023 | Buy | +388,889 | $0.90 | $350.00K | 884,290 |
| Phillip B. Donenberg Director | Aug 16, 2023 | Buy | +111,111 | $0.90 | $100.00K | 114,111 |
| R.A. Session II 10% owner | Jul 13, 2023 | Sale | −5,344 | $0.70 | $3.74K | 8,871,747 |
| R.A. Session II 10% owner | Jul 12, 2023 | Sale | −80,528 | $0.71 | $57.17K | 8,877,091 |
| R.A. Session II 10% owner | Jun 23, 2023 | Sale | −18,100 | $0.70 | $12.67K | 8,957,619 |
| R.A. Session II 10% owner | Jun 22, 2023 | Sale | −10,508 | $0.70 | $7.36K | 8,975,719 |
| R.A. Session II 10% owner | Jun 21, 2023 | Sale | −138,962 | $0.70 | $97.27K | 8,986,227 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Taysha Gene Therapies's stock actually held short. Settlement fails (shares not delivered on time) peaked at 505 shares on Sep 8, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Sukumar Nagendran Officer | Jul 10, 2026 | 200,000 | $1.30M | Jul 10, 2026 | Stock Option Grant |
| Sukumar Nagendran Officer | Apr 10, 2026 | 200,000 | $926.00K | Apr 10, 2026 | RSU Grant |
| Rumana Haque-Ahmed Officer | Feb 27, 2026 | 2,405 | $10.99K | Feb 27, 2026 | RSU Award |
| Kamran Alam Officer | Feb 4, 2026 | 1,655 | $7.81K | Feb 4, 2026 | RSU Award |
| Rumana Haque-Ahmed Officer | Feb 4, 2026 | 697 | $3.29K | Feb 4, 2026 | RSU Award |
| Sean McAuliffe Affiliate - Chief Business Officer | Feb 4, 2026 | 914 | $4.31K | Feb 4, 2026 | RSU Award |
| Fred Porter Affiliate-Chief of Staff & Tech.Op.Officer | Feb 4, 2026 | 889 | $4.20K | Feb 4, 2026 | RSU Award |
| Emily McGinnis Affiliate-Chief Pat. Adv. & Ext. Aff. Off. | Feb 4, 2026 | 901 | $4.25K | Feb 4, 2026 | RSU Award |
| Kamran Alam Officer | Jan 23, 2026 | 100,846 | $513.31K | Jan 23, 2026 | RSU Award |
| Sean McAuliffe Affiliate - Chief Business Officer | Jan 23, 2026 | 46,064 | $234.47K | Jan 23, 2026 | RSU Award |
| Emily McGinnis Affiliate-Chief Pat. Adv. & Ext. Aff. Off. | Jan 23, 2026 | 32,077 | $163.27K | Jan 23, 2026 | RSU Award |
| Rumana Haque-Ahmed Officer | Jan 23, 2026 | 30,052 | $152.96K | Jan 23, 2026 | RSU Award |
| Sukumar Nagendran Officer | Jan 23, 2026 | 113,824 | $579.36K | Jan 23, 2026 | RSU Award |
| Sean P. Nolan Officer, Director | Jan 23, 2026 | 168,078 | $855.52K | Jan 23, 2026 | RSU Award |
| Fred Porter Affiliate-Chief of Staff & Tech.Op.Officer | Jan 23, 2026 | 54,916 | $279.52K | Jan 23, 2026 | RSU Award |
See a number that looks wrong?